Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Revive Therapeutics Ltd C.RVV

Alternate Symbol(s):  RVVTF

Revive Therapeutics Ltd. is a Canada-based life sciences company. The Company is focused on the research and development of therapeutics for infectious diseases and medical countermeasures. It is engaged in exploring the use of Bucillamine for the potential treatment of nerve agent exposure and long COVID. The Company, through its diagnostics division, is evaluating a point-of-care in vitro... see more

Recent & Breaking News (CSE:RVV)

Revive Therapeutics Announces Closing of Second Tranche of Private Placement

GlobeNewswire September 19, 2025

Revive Therapeutics Announces Extension of Proposed Private Placement

GlobeNewswire September 5, 2025

Revive Therapeutics Announces Closing of First Tranche of Private Placement and Debt Settlement

GlobeNewswire August 11, 2025

Revive Therapeutics Announces Proposed Private Placement and Debt Settlement

GlobeNewswire July 30, 2025

Revive Therapeutics Clarifies Completion of Key Nerve Agent Countermeasure Study

GlobeNewswire July 8, 2025

Revive Therapeutics Nears Completion of Key Nerve Agent Countermeasure Study with Canadian Department of National Defence Highlighting Significant Stockpiling Opportunity

GlobeNewswire June 26, 2025

Revive Therapeutics Advances with Next-Generation Bucillamine Development

GlobeNewswire June 4, 2025

Revive Therapeutics Provides Update on Research Study Evaluating Bucillamine for Nerve Agent Exposure

GlobeNewswire May 12, 2025

Revive Therapeutics Announces Proposed Shares for Debt Transaction

GlobeNewswire April 21, 2025

Revive Therapeutics to Investigate Bucillamine's Potential in Cancer Treatment

GlobeNewswire April 10, 2025

Revive Therapeutics Announces Acquisition of Molecular Hydrogen Program

GlobeNewswire April 1, 2025

Revive Therapeutics Announces Results of Annual Shareholder Meeting

GlobeNewswire March 19, 2025

Revive Therapeutics Announces LOI to Acquire DiagnaMed's Molecular Hydrogen Program

GlobeNewswire March 3, 2025

Revive Therapeutics Announces Update on R&D Focus on Bucillamine for Infectious Diseases and Medical Countermeasures

GlobeNewswire February 3, 2025

Revive Therapeutics Provides Update on Research Study Evaluating Bucillamine for Nerve Agent Exposure

GlobeNewswire January 8, 2025

Revive Therapeutics Announces Publication Demonstrating Novel Therapeutic Approach of Psilocybin in Stroke

GlobeNewswire November 12, 2024

Revive Therapeutics Provides Update on Research Study Evaluating Bucillamine for Nerve Agent Exposure

GlobeNewswire October 31, 2024

Revive Therapeutics Announces Strategic Focus on Bucillamine for Infectious Diseases and Medical Countermeasures

GlobeNewswire September 18, 2024

Revive Therapeutics Provides Update on Research Study Evaluating Bucillamine for Nerve Agent Exposure and Expansion into Viral Infections

GlobeNewswire August 28, 2024

Revive Therapeutics Provides Update on Research Study Evaluating Bucillamine for Nerve Agent Exposure

GlobeNewswire July 2, 2024